Konstantinos Arnaoutakis
Title | Associate Professor |
---|
Institution | University of Arkansas for Medical Sciences |
---|
Department | Internal Med, College of Medicine |
---|
Division | Internal Med Hem-Onc |
---|
Address | 10-54 Cancer Institute 4104 Outpatient Circle Mail Slot # 508 Little Rock AR 72205
|
---|
Phone | 501-526-6990 x8064 |
---|
vCard | Download vCard |
---|
|
|
|
Overview Dr. Konstantinos Arnaoutakis is a hematologist and oncologist at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences. He is also an Associate Professor in the Department of Internal Medicine, Division of Hematology and Oncology. Dr. Arnaoutakis received his medical degree from the University of Patras Medical School in Greece. He served an internal medicine residency at Albany Medical College-Albany Medical Center Hospital. He also served a fellowship in hematology and oncology at Tufts University, St. Elizabeth's Medical Center in Boston, MA. He later went on to serve as Chief Hematology and Medical Oncology Fellow at Tufts University. He is board certified in internal medicine, hematology and oncology. He is a member of the American Medical Association, American College of Physician, American Society of Clinical Oncology and American Society of Hematology. His primary research interests are lung cancer, head and neck cancer and genitourinary cancers.
Research 331550 (UAMS C25129) (ARNAOUTAKIS, KONSTANTINOS)Aug 24, 2022 - Aug 23, 2023 Amgen, Inc. A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamabin Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301) Role: Principal Investigator |
| 331550(UAMSC25129) (ARNAOUTAKIS, KONSTANTINOS)Aug 24, 2022 - Aug 23, 2023 Amgen, Inc. A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamabin Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301) Role: Principal Investigator |
| S1929 (ARNAOUTAKIS, KONSTANTINOS)Sep 24, 2021 - Sep 23, 2031 Southwest Oncology Group-Clinical Trial Initiative S1929, Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC) (273385) Role: Principal Investigator |
| S1900B (ARNAOUTAKIS, KONSTANTINOS)Jun 26, 2020 NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group No FP attached Role: Principal Investigator |
| S1900C (ARNAOUTAKIS, KONSTANTINOS)May 18, 2020 NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group S1900C: A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study) (260760) Role: Principal Investigator |
| S1400F (ARNAOUTAKIS, KONSTANTINOS)Aug 20, 2019 NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group No FP attached Role: Principal Investigator |
| S1800A (ARNAOUTAKIS, KONSTANTINOS)Jul 3, 2019 NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group No FP attached Role: Principal Investigator |
| S1900A (ARNAOUTAKIS, KONSTANTINOS)Jul 3, 2019 NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group No FP attached Role: Principal Investigator |
| CA209817 (ARNAOUTAKIS, KONSTANTINOS)Sep 13, 2018 Bristol-Meyers Squibb No FP attached Role: Principal Investigator |
| 2015 (ARNAOUTAKIS, KONSTANTINOS)May 22, 2017 - Jun 1, 2020 NOVARTIS Pharmaceuticals Corporation A phase Ib/II, open-label, multictr trial w/ oral cMET inhibitor INC280 alone & combined with erlotinib vs platinum/pemetrexed in adult patients w/ EGFR mutated, cMET-amplified, locally advanced/metastatic NSCLC with acquired resistance to prior EGFR TKI Role: Principal Investigator |
| 2015-001241-84 (ARNAOUTAKIS, KONSTANTINOS)May 22, 2017 - Jun 1, 2020 Novartis Pharmaceuticals Corporation No FP attached Role: Principal Investigator |
| GO29527 (ARNAOUTAKIS, KONSTANTINOS)Aug 1, 2016 Genentech, Inc. No FP attached Role: Principal Investigator |
| GO29437 (ARNAOUTAKIS, KONSTANTINOS)Jun 29, 2016 Genentech, Inc. No FP attached Role: Principal Investigator |
| C4 (ARNAOUTAKIS, KONSTANTINOS)Jun 2, 2016 Genentech, Inc. GO29537 Role: Principal Investigator |
| C4-189368 (ARNAOUTAKIS, KONSTANTINOS)Jun 2, 2016 Genentech, Inc. No FP attached Role: Principal Investigator |
| VRPX-A202 (ARNAOUTAKIS, KONSTANTINOS)Jul 16, 2014 VentiRx Pharmaceuticals No FP attached Role: Principal Investigator |
| AGS (ARNAOUTAKIS, KONSTANTINOS)Sep 10, 2013 Argos Therapeutics, Inc An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS 003) Plus Standard Treatment of Advanced Renal Cell Carcinom Role: Principal Investigator |
| AGS-003-007 (ARNAOUTAKIS, KONSTANTINOS)Sep 10, 2013 Argos Therapeutics, Inc An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunother Role: Principal Investigator |
| ABT (ARNAOUTAKIS, KONSTANTINOS)Aug 23, 2013 AbbVie Inc A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy versus Plac Role: Principal Investigator |
| ABT-888 (ARNAOUTAKIS, KONSTANTINOS)Aug 23, 2013 AbbVie Inc A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy versus Plac Role: Principal Investigator |
| Afatinib 1200.43 (ARNAOUTAKIS, KONSTANTINOS)Nov 29, 2012 Boehringer Ingleheim Pharmaceuticals, Inc. A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of Role: Principal Investigator |
| Afatinib1200.43 (ARNAOUTAKIS, KONSTANTINOS)Nov 29, 2012 Boehringer Ingleheim Pharmaceuticals, Inc. A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of Role: Principal Investigator |
| BP1200.43 (ARNAOUTAKIS, KONSTANTINOS)Oct 23, 2012 Boehringer Ingleheim Bioproducts A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients Role: Principal Investigator |
| IMA901 (ARNAOUTAKIS, KONSTANTINOS)Apr 12, 2012 - Jul 31, 2014 Immatics Biotechnologies A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients receiving Sunitinib as First-Line Therapy for Ad Role: Principal Investigator |
| PAZ113758 (ARNAOUTAKIS, KONSTANTINOS)Jan 15, 2012 - Aug 10, 2015 GlaxoSmithKline A randomized, open-label, Phase II, 2-arm multi-center trial comparing maintenance therapy with pazopanib or pemetrexed in non-progressing subjects wi Role: Principal Investigator |
| PF (ARNAOUTAKIS, KONSTANTINOS)Nov 22, 2011 Pfizer, Inc. Pfizer A7471009, A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small C Role: Principal Investigator |
| PF-00299804 (ARNAOUTAKIS, KONSTANTINOS)Nov 22, 2011 Pfizer, Inc. Pfizer A7471009, A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small C Role: Principal Investigator |
| IRESSA (ARNAOUTAKIS, KONSTANTINOS)Sep 16, 2011 AstraZeneca An Open Label, Multi-center, IRESSAâ„¢ Clinical Access Program of Gefitinib 250 mg Role: Principal Investigator |
| A4021032 Phase 2 (ARNAOUTAKIS, KONSTANTINOS)Sep 9, 2010 Pfizer, Inc. A Phase 2, Randomized, Open Label Study of Figitumumab (CP-751,871) Plus Cisplatin (or Carboplatin) and Etoposide, Versus Cisplatin (or Carboplatin) a Role: Principal Investigator |
| A4021032Phase2 (ARNAOUTAKIS, KONSTANTINOS)Sep 9, 2010 Pfizer, Inc. A Phase 2, Randomized, Open Label Study of Figitumumab (CP-751,871) Plus Cisplatin (or Carboplatin) and Etoposide, Versus Cisplatin (or Carboplatin) a Role: Principal Investigator |
| A8081005 Phase 2 EML4-ALK (ARNAOUTAKIS, KONSTANTINOS)Feb 15, 2010 Pfizer, Inc. Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF-02341066 in Role: Principal Investigator |
| A8081005Phase2EML4-ALK (ARNAOUTAKIS, KONSTANTINOS)Feb 15, 2010 Pfizer, Inc. Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF-02341066 in Role: Principal Investigator |
| A8081007 Phase 3 NSCLC (ARNAOUTAKIS, KONSTANTINOS)Jan 27, 2010 - Jan 1, 2015 Pfizer, Inc. Phase III, Randomized, Open-Label Study of the Efficacy and Safety of PF-02341066 Versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Pa Role: Principal Investigator |
| A8081007Phase3NSCLC (ARNAOUTAKIS, KONSTANTINOS)Jan 27, 2010 - Jan 1, 2015 Pfizer, Inc. Phase III, Randomized, Open-Label Study of the Efficacy and Safety of PF-02341066 Versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Pa Role: Principal Investigator |
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
Don't see publications published under other names? Login to add alternative names.
-
Dizman N, Bakouny Z, Haykal T, Riano I, Desai A, Butt A, Basu A, Zhao D, Saad E, Saliby RM, Gosain R, Gosain R, Ardeshir F, Deng L, Matt-Amaral L, Arnaoutakis K, Bekaii-Saab T, Manochakian R, Marshall A, Forde P, Murphy M, Subbiah V, Chavez-MacGregor M, Owonikoko TK, Lopes G, Aggarwal C, Lee AI, Choueiri TK. Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice. JCO Oncol Pract. 2024 Oct 07; OP2400565. PMID: 39374449.
-
Arnaoutakis K, Wan Y, Elliott J, Young M, Yin Y, Leventakos K, Lin HM, Dimou A. Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC. Adv Ther. 2024 Aug; 41(8):3217-3231. PMID: 38916812.
-
Tu SM, Trikannad AK, Vellanki S, Hussain M, Malik N, Singh SR, Jillella A, Obulareddy S, Malapati S, Bhatti SA, Arnaoutakis K, Atiq OT. Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care. Cancers (Basel). 2024 Mar 14; 16(6). PMID: 38539487.
-
Ma L, Peterson EA, Shin IJ, Muesse J, Marino K, Steliga MA, Atiq O, Arnaoutakis K, Wardell C, Wooldridge J, Prior F, Johann DJ. An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics. Front Genet. 2022; 13:987175. PMID: 36846293.
-
Tu SM, Singh SR, Arnaoutakis K, Malapati S, Bhatti SA, Joon AY, Atiq OT, Pisters LL. Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench. Cancers (Basel). 2022 Jul 09; 14(14). PMID: 35884406.
-
Makhoul I, Anders M, Siegel R, Chiang A, Markham MJ, Chen RC, Mougalian S, Arnaoutakis K, Giuliani M, Im A, Kozlik MMP, Crist STS, Garrett-Mayer E, Kamal A. Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative. JCO Oncol Pract. 2022 07; 18(7):e1209-e1218. PMID: 35467961.
-
Abdallah AO, Coleman H, Kamel M, Davis R, Landrum T, Spencer H, Mackintosh S, Mahmoud FA, Milojkovic N, Wicker C, Arnaoutakis K, Nakagawa M. A novel prostate cancer immunotherapy using prostate-specific antigen peptides and Candida skin test reagent as an adjuvant. SAGE Open Med. 2018; 6:2050312118800202. PMID: 30245818.
-
Apopa PL, Alley L, Penney RB, Arnaoutakis K, Steliga MA, Jeffus S, Bircan E, Gopalan B, Jin J, Patumcharoenpol P, Jenjaroenpun P, Wongsurawat T, Shah N, Boysen G, Ussery D, Nookaew I, Fagan P, Bebek G, Orloff MS. PARP1 Is Up-Regulated in Non-small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin. Front Microbiol. 2018; 9:1757. PMID: 30127774.
-
Sherman AC, Simonton-Atchley S, Mikeal CW, Anderson KM, Arnaoutakis K, Hutchins LF, Makhoul I, Mahmoud F, Milojkovic N, Harrington SE, Suen JY. Cancer patient perspectives regarding preparedness for end-of-life care: A qualitative study. J Psychosoc Oncol. 2018 Jul-Aug; 36(4):454-469. PMID: 29863447.
-
Johann DJ, Steliga M, Shin IJ, Yoon D, Arnaoutakis K, Hutchins L, Liu M, Liem J, Walker K, Pereira A, Yang M, Jeffus SK, Peterson E, Xu J. Liquid biopsy and its role in an advanced clinical trial for lung cancer. Exp Biol Med (Maywood). 2018 02; 243(3):262-271. PMID: 29405770.
-
Makhoul I, Motwani P, Schafer L, Arnaoutakis K, Mahmoud F, Safar M, Graves D, Mehta P, Govindarajan R, Hutchins L, Thrush C. Integrating Collaborative Learning and Competition in a Hematology/Oncology Training Program. J Cancer Educ. 2018 02; 33(1):186-192. PMID: 27516202.
-
Mooradian MJ, Piotrowska Z, Drapkin BJ, Dias-Santagata D, Marcoux N, Arnaoutakis K, Nagy RJ, Lanman R, Iafrate AJ, Farago AF, Mino-Kenudson M, Hata AN, Sequist LV. Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2017; 1. PMID: 31032471.
-
Nima ZA, Alwbari AM, Dantuluri V, Hamzah RN, Sra N, Motwani P, Arnaoutakis K, Levy RA, Bohliqa AF, Nedosekin D, Zharov VP, Makhoul I, Biris AS. Targeting nano drug delivery to cancer cells using tunable, multi-layer, silver-decorated gold nanorods. J Appl Toxicol. 2017 Dec; 37(12):1370-1378. PMID: 28730725.
-
Jeffus SK, Gardner JM, Steliga MA, Shah AA, Stelow EB, Arnaoutakis K. Hyalinizing Clear Cell Carcinoma of the Lung: Case Report and Review of the Literature. Am J Clin Pathol. 2017 Jul 01; 148(1):73-80. PMID: 28927164.
-
Bansal M, Abdallah AO, Pennisi A, Arnaoutakis K, Makhoul I, Mehta P. Improving Communication on Intent of Chemotherapy Using QOPI Scores and PDSA Cycles. J Cancer Educ. 2016 12; 31(4):736-741. PMID: 26411307.
-
Kaur V, Haider S, Sasapu A, Mehta P, Arnaoutakis K, Makhoul I. Addressing Opioid-Associated Constipation Using Quality Oncology Practice Initiative Scores and Plan-Do-Study-Act Cycles. J Oncol Pract. 2017 01; 13(1):e91-e97. PMID: 28084881.
-
Mahmoud F, Abdallah AO, Arnaoutakis K, Makhoul I. Metastatic Renal Cell Carcinoma Presenting as Painful Chewing Successfully Treated with Combined Nivolumab and Sunitinib. Perm J. 2016; 20(3):15-149. PMID: 27352410.
-
Ravilla R, Joiner AK, Alapat D, Arnaoutakis K. An Unusual Case of Acute Promyelocytic Leukemia Presenting With Hypoplastic Bone Marrow and Pancytopenia. Am J Med Sci. 2016 Mar; 351(3):317-8. PMID: 26992265.
-
Arnaoutakis K, Anders M, Berry K. Simulating Four Essential Conversations with Hematology/Oncology Trainees: a Qualitative Evaluation. J Cancer Educ. 2016 Mar; 31(1):55-62. PMID: 25926020.
-
Pai VB, Ravilla R, Lindberg M, Steliga M, Arnaoutakis K. Myxoid mesenchymal neoplasm presenting as massive arm and chest wall oedema with pleural effusion. Ecancermedicalscience. 2015; 9:590. PMID: 26635894.
-
Gokden M, Ariza A, Arnaoutakis K. Molecular Markers in the Diagnosis and Treatment of Cancer. Biomed Res Int. 2015; 2015:105217. PMID: 26451364.
-
Arnaoutakis K. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2015 02 12; 372(7):683. PMID: 25671265.
-
Pandey S, Nakagawa M, Rosenbaum ER, Arnaoutakis K, Hutchins LF, Makhoul I, Milojkovic N, Cottler-Fox M. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate?) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor. J Clin Apher. 2015 Feb; 30(1):50-4. PMID: 25042026.
-
Robertson WW, Steliga MA, Siegel ER, Arnaoutakis K. Accuracy of fine needle aspiration and core lung biopsies to predict histology in patients with non-small cell lung cancer. Med Oncol. 2014 Jun; 31(6):967. PMID: 24777549.
-
Dholaria B, Alapat D, Arnaoutakis K. Primary bone marrow Hodgkin lymphoma in an HIV-negative patient. Int J Hematol. 2014 Apr; 99(4):503-7. PMID: 24532438.
-
Khetpal R, Katz MD, Cox M, Arnaoutakis K. The role of salvage hemiscrotectomy in testicular cancer after scrotal contamination: a case report and literature review. Clin Genitourin Cancer. 2014 Jun; 12(3):e103-5. PMID: 24461625.
-
Rao A, Griffiths R, Arnaoutakis K. Paralyzed by a rare cause: an unusual case of metastatic diffuse large B cell lymphoma of the intramedullary spinal cord. Ann Hematol. 2014 Feb; 93(2):337-8. PMID: 23712293.
-
Arnaoutakis K, Graves DA, Hutchins LF, Kieber-Emmons TK. Melanoma - From Early Detection to Treatment. Immunomodulation. 2013.
-
Khetpal R, Arnaoutakis K, Dholaria B. CMV esophagitis-sequelae of radiation therapy. Esophagus. 2013; 10:244-246.
-
Pandey S, Bellamy W, Arnaoutakis K, Singh ZN. Gains of 2p23/ALK locus are common in non-small cell lung carcinoma: Clinical and molecular correlations. 2012.
-
Robertson WW, Steliga M, Arnaoutakis K. Accuracy of fine needle aspiration and core lung biopsies to predict histology in patients with non-small cell lung cancer. 2012.
-
Arnaoutakis K, Ralph Buschbacher (ed). Geriatrics: Rehabilitation Medicine Quick Reference. Anemia. 2012.
-
Blanchard EM, Arnaoutakis K, Hesketh PJ. Lung cancer in octogenarians. J Thorac Oncol. 2010 Jun; 5(6):909-16. PMID: 20521358.
-
Arnaoutakis K, Oo TH. Bronchus-associated lymphoid tissue lymphomas. South Med J. 2009 Dec; 102(12):1229-33. PMID: 20016430.
-
Arnaoutakis K, Morse, A.B., Ambika, S., Wong G., Parameswaran, R. Practice-based improvement (PBI) via web based tool (WBT) in multidisciplinary gynecologic oncology clinic (MGOC). 2009.
-
Hesketh PJ, Younger J, Sanz-Altamira P, Hayden M, Bushey J, Trainor B, Krentzin M, Nowd P, Arnaoutakis K, Hesketh AM. Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer. 2009 Aug; 17(8):1065-70. PMID: 19066985.
-
Arnaoutakis K. ASCO's Career Resource Guide Helps Fellows Achieve Success. ASCO News & Forum. 2008.
-
Arnaoutakis K, Wong G, Parameswaran J. Use of a standardized web-based tool for evaluation of aromatase inhibitor related bone loss in breast cancer patients. Meeting. 2008.
-
Arnaoutakis K. Evaluation of malignant pleural effusion. Albany Medical Review. 2006; 8(2).
-
Arnaoutakis K, Mecca, P. A 69-year-old man with abdominal pain and hypotension. Albany Medical Review. 2004; 7(2).
-
Arnaoutakis K. Recurrent lung melanoma 20 years after previous cutaneous melanoma. Saratoga Upstate Annual Meeting. 2004.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2004 | 2 | 2006 | 1 | 2008 | 3 | 2009 | 2 | 2010 | 1 | 2012 | 3 | 2013 | 4 | 2014 | 3 | 2015 | 3 | 2016 | 5 | 2017 | 3 | 2018 | 5 | 2022 | 2 | 2023 | 1 | 2024 | 3 |
To return to the timeline, click here.
|
Arnaoutakis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|